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Nitric oxide (NO) promotes vasodilation through the activation of guanylate
cyclase, resulting in the relaxation of the smooth muscle vasculature and a
subsequent decrease in blood pressure. Therefore, its regulation is of interest for
the treatment and prevention of heart disease. An example is pulmonary
hypertension which is treated by targeting this NO/vasodilation pathway. In
bacteria, plants and fungi, nitrite (NO2
) is utilized as a source of NO through
enzymes known as nitrite reductases. These enzymes reduce NO2
 to NO
through a catalytic metal ion, often copper. Recently, several studies have shown
nitrite reductase activity of mammalian carbonic anhydrase II (CAII), yet the
molecular basis for this activity is unknown. Here we report the crystal structure
of copper-bound human CAII (Cu–CAII) in complex with NO2
 at 1.2 A˚
resolution. The structure exhibits Type 1 (T-1) and 2 (T-2) copper centers,
analogous to bacterial nitrite reductases, both required for catalysis. The copper-
substituted CAII active site is penta-coordinated with a ‘side-on’ bound NO2
,
resembling a T-2 center. At the N terminus, several residues that are normally
disordered form a porphyrin ring-like configuration surrounding a second
copper, acting as a T-1 center. A structural comparison with both apo- (without
metal) and zinc-bound CAII (Zn–CAII) provides a mechanistic picture of how,
in the presence of copper, CAII, with minimal conformational changes, can
function as a nitrite reductase.
1. Introduction
In mammals (including humans), it has been well established
that zinc–carbonic anhydrase (Zn–CA) catalyzes the rever-
sible hydration/dehydration of carbon dioxide (CO2)/bicar-
bonate (HCO3
) (Meldrum & Roughton, 1933; Stadie &
O’Brien, 1933). There are 12 enzymatically active CA isoforms
in humans, with CAI and II abundant in most cells, especially
in red blood cells (RBCs), and as such they are directly
involved in gas exchange, ion transport, and extra- and
intracellular pH regulation (Frost, 2014). A single Zn–CAI or
II protein is capable of converting 0.2 and 1.1  106 CO2 to
HCO3
 per second, respectively (Supuran, 2008; Steiner et al.,
1975). Hence, with a concentration of Zn–CAI and II of 4.2 
106 and 4.8  105 molecules per RBC, there are excessive
amounts of CA to regulate the 5  1020 CO2 generated in an
adult human breath (Moini et al., 2002). This excess of CA in
the blood leads to the question do carbonic anhydrases have
other regulatory roles? Many reports have shown CAII is a
promiscuous enzyme, capable of binding multiple substrates
and performing a variety of reactions besides its carbonic
anhydrase activity. These include binding other gaseous
molecules such as nitrate, nitrite and molecular oxygen;
esterase activity with many ester-containing compounds; and
hydration reactions such as hydrating cyanamide to urea
(Briganti et al., 1999; Nielsen & Fago, 2015; Mangani &
Ha˚kansson, 1992; Piazzetta et al., 2017). While these activities
are important and show CAII’s robust role, recent reports
have shown that CAII can also reduce nitrite (NO2
) to nitric
oxide (NO), and thus, may play a role in vasodilation and
regulation of blood pressure (Andring et al., 2018; Aamand et
al., 2009; Hanff et al., 2018).
CAII is a 30 kDa protein, with a solvent-exposed active site.
In Zn–CAII, the zinc is tetrahedrally coordinated by three
histidines (His94, His96, and His119) and a solvent molecule.
The active site is divided into a distinct hydrophobic and
hydrophilic side. The hydrophobic side (residues Ile91, Val121,
Phe131, Val135, Leu141, Val143, Leu198, Pro202, Leu204,
Val207 and Trp209) stabilizes the CO2 substrate, while the
hydrophilic side (Asp62, His64, Asp67, Gln92, Thr199 and
Thr200) orders and regulates the solvent [W1, W2, W3a, W3b
and WD (deep water)] required for rapid catalytic turnover
(Frost, 2014). Of special importance is His64, that modulates
between an ‘in’ and ‘out’ conformation (referring to its
direction relative to the active site), and is known to be
important in proton transfer [Fig. 1(a)] (Fisher et al., 2011). Of
note, all deposited structures of Zn–CAII to date have
disordered N termini (residues 1–4). The role of Zn–CAII in
the hydration/dehydration of CO2/HCO3
 has been extensively
studied. The reaction is a two-step ping-pong mechanism. In
the hydration direction, the first step is the nucleophilic attack
of CO2 by a zinc-bound hydroxyl that results in the formation
of HCO3
, which is displaced by a water molecule (Domsic et
al., 2008). The second step of the reaction is the transfer of a
proton from the zinc-bound water to the bulk solvent via the
well defined solvent network and His64 (Silverman &
Lindskog, 1988). The regeneration of the zinc-bound hydroxyl
permits the catalytic reaction cycle, the kcat/Km of the reaction
is 120 M1 ms1, which means Zn–CAII has evolved to near
catalytic perfection for the hydration/dehydration of CO2/
HCO3
, as it is diffusion-rate limited (Maupin et al., 2009).
In humans, the most common source of NO is its synthesis
by endothelial nitrogen oxide synthase (eNOS), which cata-
lyzes the oxidation of arginine to produce NO and citrulline
(Feng, 2012). While this enzyme is responsible for NO
production under normoxia, under hypoxic conditions the
enzyme is acatalytic (Lundberg et al., 2008). Thus, other less
understood pathway(s) have been suggested to function in the
place of eNOS during times of low oxygen to produce NO
through a nitrite reduction pathway. Nitrite represents an
untapped source of NO in the blood with little understanding
of how it is reduced. Although, previous studies have
suggested hemoglobin or a CA as likely candidates as the
nitrite reductase (Lundberg et al., 2008; Sparacino-Watkins et
al., 2012).
Bacterial copper nitrite reductases utilize two separate and
distinct copper-binding sites to catalyze the reduction of
nitrite. The first copper site, known as the Type I (T-1) site and
coordinated by a cysteine, a methionine and two histidines,
functions to transfer electrons to the second copper site
termed the Type II (T-2) site (see Fig. S1 in the supporting
information) (Li et al., 2015). The T-2 site, coordinated by
three histidines and a solvent molecule, is where the nitrite
reduction reaction occurs (Li et al., 2015). It is interesting to
note that previous studies have commented on the striking
similarity between the Zn–CAII active site and bacterial
nitrite reductase T-2 sites, suggesting that CAII may be
involved in mammalian nitrite reduction (Strange et al., 1995).
In addition, recent studies have shown that bovine CAII can
reduce NO2
 to NO (Aamand et al., 2009). However, when
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Figure 1
Structure of Zn– and Cu–CAII: active site and water network. (a) Zn–
CAII. The zinc metal is stabilized by three histidines (His94, His96 and
His119). His64 is depicted in its dual ‘in’ and ‘out’ conformations. The N
terminus (residues 1–4) is disordered. The substrate CO2 is shown bound
adjacent to the zinc, stabilized by the hydrophobic pocket (Domsic et al.,
2008). (b) Cu–CAII. The copper metal (T-2 site) is stabilized by the same
three histidines as the zinc. Also, His64 was observed in dual
conformations. The NO2
 bound with an oxygen and a nitrogen
interacting with the copper. The water network resembles that observed
in Zn–CAII, with the exception of the extended water network (W4 and
W5), creating a hydrogen-bonding network spanning from the N
terminus to the active site. The N terminus is ordered, forming a
pseudo-porphyrin ring around a second copper (T-2 site). The catalytic
metals are depicted as spheres: zinc (magenta) and copper (brown). The
hydrophobic residues (Ile91, Val121, Phe131, Val135, Leu141, Val143,
Leu198, Pro202, Leu204, Val207 and Trp209) are highlighted as orange
and the hydrophilic residues (Asn62, His64, Asn67, Gln92, Thr199 and
Thr200) as violet. The active-site solvent network (W1, W2, W3a and
W3b) is depicted as red spheres and the extended water network (W4 and
W5) is shown in the Cu–CAII substituted structure.
dialyzed with ethylenediaminetetraacetic acid (EDTA), the
enzyme retained its carbonic anhydrase activity yet lost its
nitrite reductase activity (Hanff et al., 2018). While zinc is a
divalent cation, it has a full d orbital when coordinated in
CAII, and thus, is unable to perform redox reactions. The two
observations, taken together, suggest that there may be a
factor in blood that activates the nitrite reductase activity of
CAII. In blood, there is a relatively high concentration of
copper (15 mM), which can replace the zinc in the CAII
active site, as previous research has shown that CAII prefer-
entially binds copper with 50-fold specificity over zinc
(Schultze et al., 2014; Ha˚kansson et al., 1994; Hunt et al., 1999).
Hence, based on the knowledge of copper-containing bacterial
nitrite reductases, we hypothesized that copper was the
additional cofactor in blood responsible for the nitrite
reductase activity of CAII previously reported. Therefore, the
addition of copper to apo-CAII (without metal) could be the
mechanism to convert CAII to a nitrite reductase. In this
study, we compared the crystal structures of Cu– with both
apo- and Zn–CAII (see Methods) to obtain a mechanistic
picture of how, in the presence of copper, CAII can, with
minimal conformational changes, be converted into a nitrite
reductase.
2. Results
Mammalian CAs selectively use zinc as their catalytic metal
ion, using it as a Lewis acid to increase the nucleophilic
character of the zinc-bound hydroxyl. The CA active site, as
described above, has the same characteristics as a T-2 copper-
binding site in bacterial nitrite reductases: three coordinating
histidines, polar residues for charged transition-state stabili-
zation and metal-bound solvent molecules. Our crystal struc-
ture confirmed this, with the Cu–CAII T-2 site having the same
general conformation as the zinc active site. The copper atom
is penta-coordinated via the three histidine residues (His94,
His96 and His119), and a nitrite molecule, bound in a ‘side-on’
conformation, coordinated via an oxygen and a nitrogen (Fig.
1). The copper-substituted active site forms a T-2 site perfectly,
as described in bacterial copper nitrite reductases.
As mentioned previously, an ordered water network exists
within Zn–CAII, responsible for rapid proton transfer [Fig.
1(a)]. In the active site, the Cu–CAII has a slightly altered
water network compared with the Zn–CAII structure [Fig.
1(b)] in that the zinc-bound solvent is replaced with a bound
NO2
 molecule in a ‘side-on’ configuration (Fig. 2). This was
unexpected, as no nitrite or nitrogen source was added to the
crystallization conditions (1.6 M sodium citrate and 50 mM
Tris at a pH of 7.8). However, previous structural studies of
bacterial copper nitrite reductases have revealed endogenous
ligands bound to the T-2 site (Antonyuk et al., 2005; Fukuda et
al., 2015). Both NO2
 and NO have been shown to be bound in
the Achromobacter cycloclastes T-2 copper site without being
added to the crystal (Fig. S1). While the origin of these ligands
is unknown, others have hypothesized synchrotron radiation
as a possible source of high-energy ions leading to the
formation of these molecules (Fukuda et al., 2015). One of the
NO2
 oxygens occupies the position of the Zn–CAII deep
water, which is important for solvent replenishment (Kim et
al., 2016, 2018). Comparison of the Zn–CAII:CO2 complex
(PDB entry 5yui, Kim et al., 2016) with the Cu–CAII:NO2

complex shows significant differences. While the NO2
 binds
directly to the copper and forms stabilizing interactions with
the hydrophilic pocket, the CO2 binds in a ‘side-on’ confor-
mation adjacent to the zinc and is stabilized by the hydro-
phobic pocket (Fig. 2). The NO2
 is stabilized via hydrogen
bonding to residues Thr199 and Thr200 while also interacting
with W1 [Fig. 2(b)]. The CO2 binding shares the same
hydrogen bond with Thr199 while also forming hydrophobic
interactions with Val121, Val143 and Trp209 [Fig. 2(a)]. The
Cu–CAII active site retains the same W1, W2, W3a and W3b
positions as Zn–CAII (Fig. 1). However, in Cu–CAII an
extended ordered water network exists spanning past His64,
forming a hydrogen-bonding network up to the second
copper-binding site located at the N terminus. This network is
achieved with the ordering of two additional waters compared
with the Zn–CAII, named W4 and W5 [Fig. 1(b)]. Presumably,
the additional water molecules complete a solvent network to
span the two copper-binding sites, allowing the electron
transfer necessary for the nitrite reductase reaction [Fig. 1(b)].
Mammalian CAIIs have a unique conserved N-terminus
sequence (MSHHW) not observed in the other CA isoforms
(https://www.uniprot.org/). However, as previously mentioned,
this sequence is disordered in all the Zn–CAII crystal struc-
tures deposited in the Protein Data Bank [Fig. 3(a)] (Avvaru et
al., 2010; Saito et al., 2004). The high-resolution structure of
Zn–CAII (PDB entry 3ks3, Avvaru et al., 2010) only shows
order of the N terminus starting at His4, while the apo-CAII
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Figure 2
Active site of Zn– and Cu–CAII (T-2 site) with bound substrate, CO2 and
NO2
, respectively. (a) CO2 binding site in Zn–CAII active site (adapted
from PDB entries 3ks3, Avvaru et al., 2010; 5yui, Kim et al., 2016). CO2
binds adjacent to the zinc, 2.8 A˚ from the catalytic zinc-bound solvent.
The CO2 is stabilized via interactions with residues Val121, Val143,
Leu198 and Trp209. Thr199 also forms a hydrogen bond with CO2 via its
nitrogen. (b) NO2
 binding site in Cu–CAII active site. NO2
 binds directly
to the copper, displacing the copper-bound solvent. It binds in a ‘side-on’
conformation via an oxygen and a nitrogen, 2.1 and 2.8 A˚ from the
copper, respectively. However, solvent W1 retains its position and forms
hydrogen bonds with an oxygen of NO2
. Thr199 forms two hydrogen
bonds with the bound NO2
 while Leu198 also forms stabilizing
interactions. The catalytic metals are depicted as spheres: zinc (magenta)
and copper (brown). The active-site solvent molecules are depicted as red
spheres.
structures also show some order of His3 (Fig. S2). However, in
the Cu–CAII structure, the N terminus becomes ordered,
forming a pseudo-porphyrin ring, with the copper coordinated
by several nitrogens [Fig. 3(a)]. Previous work using para-
magnetic nuclear magnetic resonance (NMR) techniques and
X-ray absorption spectroscopy predicted this N-terminal
structure as an amino terminal copper and nickel (ATCUN)
binding motif as a high-affinity binding site for copper, Kd ’
0.5 nM (Nettles et al., 2015). As confirmed from our X-ray
crystallography, this structure acts as the T-1 copper site,
coordinated to the main chain nitrogens of Ser2, His3 and
His4 [Fig. 3(a)]. It is more than likely that this site serves as the
site of electron transfer to the T-2 copper active site [Fig. 1(b)].
The pseudo-porphyrin ring conformation, formed by the Cu–
CAII N terminus has a striking resemblance to that of heme-
containing nitrite reductases [Fig. 3(b)]. Structural super-
position of the Cu–CAII N terminus with Pseudomonas
aeruginosa nitrite reductase heme gave a root-mean-square
deviation (RMSD) of 0.3 A˚ [Fig. 3(c)]. While not a porphyrin
ring structure, this pseudo T-1 site, which has not previously
been observed in metal–CAII structures, would provide the
necessary electron donor site required for nitrite reduction.
Hence, this structure provides an obvious mechanism for Cu–
CAII to function as a nitrite reductase. Based on published
mechanistic studies with bacterial nitrite reductase, the Cu–
CAII active site has the T-1 and T-2 sites, the necessary
bridging waters, and acidic residues to stabilize NO2
 and its
intermediates, thus catalyzing nitrite reduction (Fig. 4) (Feng,
2012; Li et al., 2015).
3. Discussion and conclusions
As previously reported through NMR and X-ray crystal-
lography studies, copper-substituted CAII has two binding
sites for the metal cation, one in the canonical
active site and one near the N terminus
(Ha˚kansson et al., 1994; Nettles et al., 2015).
However, previous reports showed the
secondary copper-binding site to be between
His4 and His64, while our data, for the first
time, shows a conformational change in the N
terminus, forming a pseudo-porphyrin ring to
bind a second copper. This new site is of
mechanistic importance as the proton-
shuttling residue His64 is free to undergo its
conformational change required for carbonic
anhydrase activity. Zn–CAII is known to be
inhibited by copper, which coincides with the
His4–His64 binding site reported by PDB
entry 5eoi (Ferraroni et al., unpublished work;
Lionetto et al., 2016). This work showed that if
zinc is bound in the active site, copper binds
through His64, thus proton transfer is inhib-
ited. Interestingly, our work shows that if both
sites are occupied by copper, His64 is unper-
turbed, allowing proton- or hypothetically
electron-transfer between the two copper
sites.
The water network within CAII has been extensively
studied through structural and kinetic experiments (An et al.,
2002; Boone et al., 2014; Duda et al., 2003). Previous to this
work, the ordered water network was thought to have stopped
at the proton-shuttling residue His64. However, if copper is
bound in both binding sites, we showed that the ordered water
network further extends past His64, connecting the N-term-
inal binding site to the canonical binding site through a series
of hydrogen bonds. Bacterial nitrite reductases are also known
to have ordered waters within their active sites responsible for
proton donation/acceptance and ordering substrate binding,
similar to the water network of CAII (Li et al., 2015). Marcus
theory was originally developed to study the rate of electron
transfer between ions (Marcus, 1964). The theory is used to
determine activation energy in simple systems by calculating
reorganization energies upon electron transfer. This takes into
account the donor and acceptors’ size and distance apart, as
well as dielectric constants and charge transferred (Marcus,
1964). This powerful tool can be used to study the dynamics
and movement of electrons in solution. While originally only
used for simple solutions, in the 1990s it was applied to large-
scale biological systems, such as proteins, to calculate energy
barriers in enzymatic function involved with electron transfer.
However, in 1993 Dr Silverman applied Marcus theory to
carbonic anhydrase to calculate the activation energy asso-
ciated with proton transfer (Silverman, 2000). As previously
mentioned, CA has an ordered water network with spanning
hydrogen bonds that connect the zinc-bound hydroxyl to bulk
solvent. With some modifications, Dr Silverman applied the
Marcus theory to this water network to calculate the activation
energy associated with the proton-transfer step of the CA
mechanism (Silverman, 2000). He showed that this modified
Marcus theory very accurately predicted the observed rates of
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Figure 3
N terminus of Cu–CAII (T-1 site). (a) The T-1 copper is stabilized by the N terminus of Cu–
CAII by residues Ser2, His3 and His4. The copper is also hydrogen bonded to solvent
molecule facing His64 (presumably for electron transfer to the T-2 site). Interestingly,
residue His3 adopts dual conformations, one away and one towards the copper (for electron
density refer to Fig. S3). (b) Structure of an iron-containing porphyrin ring from
P. aeruginosa nitrite reductase (PDB entry 1n15, Nurizzo et al., 1999). (c) Superposition
of Cu–CAII N terminus with the P. aeruginosa nitrite reductase heme with an RMSD of
0.27 A˚. It is important to note that the N terminus T-1 site is less ordered in comparison to
the rest of the structure. The occupancy and B factor of the T-1 site are 0.71 and 29.1 A˚2
respectively, while for the T-2 site the occupancy and B factor are 1.00 and 11.4 A˚2
respectively. This is because the N terminus needs to be transient, only forming when needed
in the blood, effectively acting as an on/off switch. Also, this transient feature would allow
rapid metal exchange, allowing trace metals in the blood to quickly bind and disassociate for
electron transfer.
CA proton transfer. However, Marcus theory has seen little
success accurately predicting proton transfer except in one
other enzyme, cytochrome c oxidase (Garbuz et al., 2017). This
protein, like CA, is involved with both proton and electron
transfer. Perhaps the reason that Marcus theory so accurately
predicts CA proton transfer is that the water network is
optimized for both proton and electron transfer depending on
the metal cation bound, thus making the theory inter-
changeably work with either electrons or protons.
While it is accepted that zinc-bound CAII exists in the
blood, there is currently no direct experimental evidence to
suggest the existence of copper-bound CAII. However,
previous work from Aamand et al. showed that bovine CAII,
when purified from bovine blood, has nitrite reductase activity
(Aamand et al., 2009). Furthermore, if this bovine CAII was
dialyzed against EDTA, the nitrite reductase activity was
ablated indicating that a metal cofactor within the bovine
blood was needed for the CAII-dependent nitrite reductase
activity (Andring et al., 2018; Hanff et al., 2018). The work
presented here indicates that the metal cofactor is copper, thus
strongly supporting the existence of Cu–CAII in blood.
Furthermore, with the known concentration of copper in
blood, paired with the high-affinity copper-binding sites, it is
extremely likely that many CAII molecules exist with two
bound copper atoms. Zinc is one of the most abundant trace
metals in the blood, with typical concentrations of 96 mM.
However, copper also has relatively high concentrations in
blood, typically 15 mM, sevenfold lower than zinc (Schultze
et al., 2014). Previous work using a colorimetric 4-(2-pyridyl-
azo)resorcinol assay showed that the CAII Kd for copper is
17 fM, while zinc Kd is 800 fM, indicating that CAII has 50-fold
specificity toward copper over zinc (Hunt et al., 1999).
Furthermore, this research from Hunt et al. indicated that
while the affinity is higher for copper than zinc, copper
removal from the active site is facilitated through EDTA while
EDTA has no effect on zinc removal from the active site
(Hunt et al., 1999). This coincides with the previous observa-
tion that EDTA prevented nitrite reductase activity (copper
dependent) while not affecting carbonic anhydrase activity
(zinc dependent) (Andring et al., 2018). The high CAII affinity
for copper over zinc is a well documented phenomenon with
many papers proving that CAII’s affinity is much higher for
copper than for zinc (Hunt et al., 1999; Thompson et al., 1999;
McCall et al., 2000, 2004),
Xi ¼
Mi
 
Ki
1 þP Mi
 
Ki
;
where Xi is the mole fraction of CA bound to the metal, Mi is
the molar concentration of total copper in blood and Ki is the
binding constant (Ka) of Cu–CAII.
Using the calculations outlined by Thompson et al. and the
affinities and concentrations from above, we can predict that
86% of CAII in the blood will have copper bound in the
canonical active site (Thompson et al., 1999). With the
secondary site having an approximate Kd of 500 nM for
copper, we suspect a substantial amount of bound Cu–CAII in
the blood (Nettles et al., 2015).
This study provides a feasible mechanistic view of how Cu–
CAII can function as a nitrite reductase, given the physio-
logical concentrations of CAII and copper in the blood. It
would seem that CAII has the conformational ability to switch
activity from a carbonic anhydrase to a nitrite reductase,
dependent on the metal ion availability. Formation of Cu–
CAII may explain nitrite reduction by cells under hypoxic
conditions, allowing the formation of NO in RBCs. We feel
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Figure 4
Proposed Cu–CAII nitrite reductase mechanism. (a) Cu–CAII in the
resting state with a copper-bound solvent molecule. Thr199 is slightly
acidic because of interactions with Glu106 allowing Thr199 to stabilize
the solvent molecule. W1 is stabilized via hydrogen bonding to Thr200
and W2 (not shown for clarity). (b) NO2
 enters the active site, displacing
the copper-bound solvent. NO2
 binds in a ‘hat’ conformation, with both
oxygen atoms coordinating to the copper. One oxygen is primed for
catalysis via hydrogen bonding to the hydroxyl of Thr199 and W1. (c)
Intermolecular electron transfer from the T-1 copper site, donating an
electron to the T-2 copper site and generating a Cu+ cation in the T-2
active site. This triggers a binding-mode change in NO2
 from ‘hat’ to
‘side-on’ coordination. One oxygen is uncoordinated from the copper and
stabilized via the nitrogen from Thr199 while the other oxygen retains
hydrogen bonding to Thr199 and W1. (d) Reduction of nitrite begins via
an electron donation from Cu+, resulting in a cascade of electron
rearrangement and the regeneration of Cu2+. The primed oxygen accepts
two protons from W1 and the acidic hydroxyl of Thr199 forming a bound
water molecule. (e) The nitrite molecule is now reduced to nitric oxide
and transiently bound to the Cu2+ cation along with the generated water
molecule. As the water molecule forms, the nitric oxide is released from
the copper. More protons are shuttled into the active site via the CA
proton-shuttle His64 and the necessary catalytic protons are replenished
regenerating the resting state in (a) (Duda et al., 2001).
these results clearly imply that we should re-examine the
possible physiological role of Cu–CAII in blood.
4. Materials and methods
Human CAII was expressed and purified according to
previously published protocols (Pinard et al., 2013; Tanhauser
et al., 1992). Briefly, a CAII gene-containing plasmid under the
control of a T7 promoter was transformed into competent
BL21 Escherichia coli cells via a standard BL21 transforma-
tion protocol. Following transformation, the E. coli cells were
grown overnight in 100 ml of nutrient-rich Luria broth. Cells
were then transferred to a large-scale 1 l culture in the
presence of a selecting antibiotic and allowed to grow to an
optical density of 0.6 at 600 nm. The cells were then induced
by the addition of 0.5 mM isopropyl -d-1-thiogalactoside
(IPTG) and 1 mM zinc sulfate and incubated for an additional
3 h. The zinc was added to aid in protein expression and
folding, thus improving the yield. The cells were pelleted via
centrifugation and subsequently lysed using a microfluidizer
set to 18 000 PSI (1 PSI’ 6895 Pa). The Zn–CAII was purified
from the cell lysate using affinity chromatography with a p-
aminomethyl-benzenesulfonamide affinity column. The final
protein stock was buffer exchanged with storage buffer
(50 mM Tris; pH 7.8) using a centrifugal filter. Purity was
determined with SDS–PAGE and protein concentration was
determined by UV–Vis spectroscopy at 280 nm.
In order to generate the copper-substituted CAII, the first
step was to remove the zinc, generating apo-CAII. Immedi-
ately following purification, Zn–CAII was diluted to a
concentration of 1 mg ml1 in storage buffer and incubated
with 5 chelation buffer (500 mM pyridine-2,6-dicarboxylic
acid; 125 mM MOPS; pH 7.0). The solution was then gently
stirred overnight at room temperature (20C) and then passed
over the p-aminomethyl-benzenesulfonamide affinity column.
Any residual Zn–CAII attached to the column, while the apo-
CAII was collected in the flow through. The apo-CAII was
buffer exchanged using centrifugal filters against storage
buffer to remove any residual chelating agent. The loss of
enzyme activity was verified using a standard colorimetric
esterase based kinetic method, as described elsewhere (Uda et
al., 2015).
Apo-CAII crystals were grown via the hanging-drop vapor-
diffusion method. Crystal trays were set up with 500 ml of
mother liquor in the well, containing 1.6 M sodium citrate and
50 mM Tris at a pH of 7.8. Hanging drops of 9 ml were utilized
consisting of a 1:1 ratio of 10 mg ml1 protein to mother
liquor. Crystal trays were left undisturbed at room tempera-
ture and apo-CAII crystal growth was observed after three
days. To generate copper-substituted CAII crystals, the
preformed apo-CAII crystals were incubated with 1 ml of a
10 mM stock solution of CuCl2 in the hanging drops. The
addition of 10 mM CuCl2 did not result in osmotic shock to the
crystals; however, concentrations greater than 50 mM resulted
in cracked brittle crystals.
The Zn–CAII crystals were grown in the same fashion as
the apo-CAII crystals. Crystal trays were set up with 500 ml of
mother liquor in the well, containing 1.6 M sodium citrate and
50 mM Tris at a pH of 7.8. Then, 5 ml hanging drops were
utilized consisting of a 1:1 ratio of 10 mg ml1 protein to
mother liquor. Crystal trays were left undisturbed at room
temperature and Zn–CAII crystal growth was observed the
next day.
The crystals were harvested utilizing MiTeGen loops, flash
cooled in liquid nitrogen and shipped to Stanford Synchrotron
Radiation Lightsource (SSRL). Data were collected at the 9-2
beamline at SSRL using a PILATUS 6M detector with 0.3
oscillations, a wavelength of 0.9795 A˚ and a detector distance
depending on the resolution of the crystal diffraction. Each
dataset consisted of 600 images for a total of 180 of data.
X-ray absorption spectroscopy was also performed at the 9-2
beamline to determine the presence of copper or zinc in the
respective crystals (Figs. S4–S6).
The diffraction images were indexed and integrated using
XDS then merged and scaled to the P21 space group using the
program AIMLESS via the CCP4 program suite (Kabsch,
2010; Evans & Murshudov, 2013). The diffraction data was
phased with standard molecular replacement methods using
the software package Phenix (Liebschner et al., 2019) using the
CAII PDB entry 3ks3 (Avvaru et al., 2010) as the search model
(Adams et al., 2010). Coordinate refinements were calculated
using Phenix, while the program Coot was utilized to add
solvent molecules and make individual real-space refinements
of each residue when needed (Adams et al., 2010; Emsley &
Cowtan, 2004). Figures were generated in the molecular
graphical software PyMOL and protein–ligand interactions
and bond lengths were determined using LigPlot+ (Schro¨-
dinger, LLC; Laskowski & Swindells, 2011). For the crystal-
lographic data-collection and refinement statistics refer to
Table S1 in the supporting information. The apo- and Cu–
CAII structures have been deposited in the PDB with acces-
sion numbers 6pea and 6pdv, respectively.
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